METHODS: This study was a randomized, single-center, double-blinded, placebo-controlled trial involving 200 patients who underwent unilateral retrograde intrarenal surgery. Patients received either tamsulosin (0.4 mg) or placebo 1 week before surgery until stent removal. Patients were randomly assigned to one of four groups. Group 1 received tamsulosin throughout the study period. Group 2 received tamsulosin before surgery and placebo after surgery. Group 3 received placebo before surgery and tamsulosin after surgery. Group 4 received placebo before and after surgery. The USSQ (Ureteral Stent Symptom Questionnaire) was completed between postoperative days 7 and 14 immediately before stent removal.
RESULTS: A total of 160 patients were included in this analysis. Their mean age was 55.0±11.0 years, and 48 patients (30.0%) were female. In the group that received preoperative tamsulosin, the success rate of 12/14F UAS deployment was significantly higher than that of the preoperative placebo group (88.0 vs. 75.3%, p=0.038). Preoperative and postoperative tamsulosin did not significantly alleviate symptoms related to the ureteral stent.
CONCLUSIONS: Our results revealed that preoperative administration of tamsulosin improved the success of larger-sized UAS, whereas preoperative and postoperative tamsulosin use did not significantly alleviate symptoms related to ureteral stents.
方法:这项研究是一项随机的,单中心,双盲,纳入200例接受单侧逆行肾内手术的患者的安慰剂对照试验.患者在手术前1周接受坦索罗辛(0.4mg)或安慰剂,直到支架移除。患者被随机分配到四组中的一组。第1组在整个研究期间接受坦索罗辛。第2组手术前接受坦索罗辛,手术后接受安慰剂。第3组手术前接受安慰剂,手术后接受坦索罗辛。第4组手术前后接受安慰剂。USSQ(输尿管支架症状问卷)在术后第7天至第14天之间在支架移除之前立即完成。
结果:本分析共纳入160例患者。他们的平均年龄为55.0±11.0岁,48例(30.0%)为女性。在接受术前坦索罗辛的组中,12/14FUAS部署的成功率明显高于术前安慰剂组(88.0vs.75.3%,p=0.038)。术前和术后坦索罗辛没有明显缓解与输尿管支架相关的症状。
结论:我们的结果表明,术前服用坦索罗辛可以提高大型UAS的成功率,而术前和术后使用坦索罗辛并未显著缓解与输尿管支架相关的症状.